Table 3 Logistic regression multivariate model showing the average effect of being admitted in the second wave after adjusting for confounding variables.
Death | Adjusted odds ratio (95% CI) | p-value |
|---|---|---|
Second wave | 0.35 (0.24–0.52) | < 0.001 |
Age (years) | ||
70–79 | 1 (ref.) | |
80–89 | 1.88 (1.65–2.15) | < 0.001 |
≥ 90 | 2.32 (1.91–2.81) | < 0.001 |
Female sex | 0.64 (0.57–0.71) | < 0.001 |
Age-adjusted Charlson comorbidity index | ||
Moderate (3–4) | 1 (ref.) | |
Severe (> 4) | 1.45 (1.27–1.66) | < 0.001 |
Arterial hypertension | 1.00 (0.89–1.14) | 0.957 |
Arterial stiffnessa | 0.86 (0.77–0.96) | 0.007 |
Severe dependenceb | 1.65 (1.42–1.91) | < 0.001 |
Days from beginning of symptoms | 0.95 (0.94–0.96) | < 0.001 |
Clouding of consciousness | 1.76 (1.54–2.02) | < 0.001 |
Tachypnea | 1.92 (1.71–2.15) | < 0.001 |
Oxygen saturation/FiO2 ratio | 1.00 (0.99–1.00) | < 0.001 |
Blood glucose (mg/dL) | ||
< 140 | 1 (ref.) | |
140–179 | 1.25 (1.08–1.44) | 0.003 |
≥ 180 | 1.45 (1.24–1.68) | < 0.001 |
Inflammatory patternc | ||
Low | 1 (ref) | |
Moderate | 1.44 (0.75–2.78) | 0.277 |
Severe | 3.66 (1.94–6.92) | < 0.001 |
Bilateral pneumonia | 1.37 (1.22–1.55) | < 0.001 |
Tocilizumab | 0.91 (0.73–1.12) | 0.372 |
Remdesivir, start date | ||
No | 1 (ref.) | |
Yes, ≤ 10 days from beginning of symptoms | 0.52 (0.36–0.75) | 0.001 |
Yes, > 10 days from beginning of symptoms | 0.63 (0.26–1.50) | 0.294 |
Systemic corticosteroids | 1.14 (1.00–1.29) | 0.047 |
Ventilatory support | ||
No | 1 (ref.) | |
Non-invasive | 4.09 (3.41–4.89) | < 0.001 |
Invasive | 6.36 (4.99–8.11) | < 0.001 |
Wave#severe dependenced | 1.50 (1.14–1.97) | 0.004 |
Wave#systemic corticosteroidse | 1.59 (1.09–2.33) | 0.017 |
Constant | 0.31 (0.15–0.64) | 0.002 |